Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1622 1638 1641 1657 1677 1796 1799
This examiner grants 74% of resolved cases
Rebecca M. Giere, in Tech Center 1700 and Art Unit 1622, has resolved 518 cases with an allowance rate of 73.7%. The median days to allowance is 1119, indicating a solid success rate with a moderate timeline. This 1119-day figure and the 73.7% allowance rate provide a clear framework for practitioners. The 73.7% rate suggests a high probability of success for those who navigate the prosecution process effectively.
The interview lift is 32.3%, which is a very high increase compared to the 73.7% allowance rate. This 32.3% lift suggests that interviews are an exceptionally powerful tool for this examiner. With 518 resolved cases, the data indicates that direct communication is a key factor in successful outcomes. Practitioners should prioritize interviews to take advantage of the 32.3% lift and navigate the 1119-day median pendency. These metrics are essential for strategic planning in Art Unit 1622.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17859292 | IMMUNOLOGICAL TEST METHOD | Final Rejection | FUJIFILM Corporation |
| 18509717 | BIOMARKERS FOR USE IN DETERMINING TRAUMATIC BRAIN INJURY (TBI) | Non-Final OA | Abbott Laboratories |
| 18560106 | METHODS OF ANALYZING SHAPED PARTICLES CONTAINING CELLS USING FLUORESCENCE ACTIVATED CELL SORTING | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 19045994 | NANOSENSOR METHODS AND APPARATUSES FOR DETERMINATION OF ANALYTES | Non-Final OA | President and Fellows of Harvard College |
| 18027202 | 3D-PRINTED MODULAR MICROCHIP WITH AN INTEGRATED IMPELLER PUMP TO MODEL INTER-ORGAN COMMUNICATION | Non-Final OA | University of Virginia Patent Foundation |
| 17924010 | DEVICES, ASSAYS AND METHODS OF TESTING PREECLAMPSIA | Non-Final OA | CEDARS-SINAI MEDICAL CENTER |
| 18108171 | HYDROGEL MICROPARTICLES FOR APPLICATIONS IN CELL AND PARTICLE SEPARATION | Final Rejection | The Charles Stark Draper Laboratory, Inc. |
| 18612744 | NANOPORE BASED MOLECULAR DETECTION AND SEQUENCING | Non-Final OA | Roche Sequencing Solutions, Inc. |
| 18042032 | MICROFLUIDIC ASSAY DEVICE | Non-Final OA | Duke University |
| 18043999 | ALLERGIC DISEASE DETERMINATION METHOD AND DETERMINATION SYSTEM | Final Rejection | NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY |
| 18302603 | BIOMARKERS FOR CBL, AND COMPOSITIONS AND METHODS FOR THEIR USE | Non-Final OA | NURIX THERAPEUTICS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy